TB-500 Side Effects: What the Research Shows

TB-500 Safety Profile in Research

TB-500 side effects in the peer-reviewed literature are primarily characterized through two bodies of evidence: animal model tolerability data and human Phase I adverse event reporting for full-length Thymosin Beta-4 (Tβ4). The synthetic fragment TB-500 (Ac-LKKTETQ) itself has no published human safety trial.

In preclinical rodent studies across wound healing, ligament, cardiac, and muscle models, Thymosin Beta-4 is generally reported as well tolerated. The chronic administration study by Spurney et al. (2010) — 150 µg IP twice weekly for 6 months in dystrophin-deficient mdx mice — noted no overt toxicity signals, though it also found no functional strength improvement ^[16].

For full-length Tβ4 in humans:

Ruff et al. 2010: In 40 healthy volunteers, intravenous single doses of 42, 140, 420, and 1260 mg produced adverse events that were infrequent and mild or moderate in intensity. No dose-limiting toxicities. No serious adverse events. Compound was considered acceptable for further cardiac ischemia studies ^[9].

Wang et al. 2021: In 40 healthy Chinese volunteers receiving multiple ascending doses, full-length recombinant Tβ4 was safe and well tolerated with no dose-limiting toxicities, dose-proportional pharmacokinetics, and no accumulation on repeat dosing ^[10].

Sosne et al. 2015 (Phase 2 ophthalmic): RGN-259 (0.1% Tβ4 topical ophthalmic) produced no serious adverse events in 9 patients over 28 days ^[8].

The gap: none of these trials characterized the safety of the TB-500 synthetic fragment (Ac-LKKTETQ) specifically. Extrapolating from the full Tβ4 safety data to the 7-residue fragment is plausible given the fragment's smaller size and simpler structure, but it is not validated.

Reported Side Effects of TB-500

In animal studies, TB-500 and Tβ4 are generally well-tolerated at the doses studied. No significant organ toxicity was reported across wound, ligament, cardiac, or muscle models in the available peer-reviewed literature.

Anecdotal adverse events reported in human community contexts include:

• Injection-site reactions (redness, swelling, mild pain at the injection site)
• Temporary fatigue following administration
• Mild dizziness or lightheadedness

These observations come from anecdotal reports, not controlled safety studies. They are noted here because they are the most commonly described human-context adverse events in the community literature; they are not documented in peer-reviewed clinical trials of the TB-500 fragment itself.

Long-term human safety data for TB-500 does not exist in peer-reviewed form. The Phase I trials for full-length Tβ4 were short-term (14-day dosing periods) and used small samples (40 subjects each) — they do not characterize chronic safety.

TB-500 and BPC-157 Combination: Safety Considerations

No formal human safety study exists for the TB-500 + BPC-157 combination. The combination has not been tested in a controlled animal study published in indexed peer-reviewed literature either.

Anecdotal reports in community contexts cite adverse events similar to those reported for each compound individually — injection-site reactions and fatigue being the most common — without documented additive or synergistic toxicity in the available literature. The theoretical mechanistic overlap (both compounds affect angiogenic and tissue repair pathways) raises no obvious pharmacodynamic toxicity concern based on the independent preclinical data, but this is extrapolation, not evidence.

This literature digest covers what is published. For the TB-500 and BPC-157 combination, the honest position is: the combination clinical data does not exist.

General Peptide Safety Considerations

Research peptides as a class carry risks that apply broadly, regardless of the compound's individual safety profile:

Purity: Unregulated commercial sources produce research peptides without the quality controls required for pharmaceutical manufacturing. Contaminants, bacterial endotoxins, peptide impurities, and incorrect sequences have been documented in the research-peptide market. These are manufacturing risks, not pharmacological risks inherent to the compound.

Injection-site risk: Any injectable compound carries inherent injection-site infection risk if sterile technique is not maintained.

Unknown long-term effects: No long-term human safety data exists for TB-500 or the synthetic fragment specifically. Short-term Phase I trials with small samples are not sufficient to characterize rare or delayed adverse events.

Immune response: Exogenous peptides can trigger immune responses, including anti-peptide antibody formation. This has not been reported as a problem in the Tβ4 Phase I trials, but it is a theoretical concern for repeat administration.

WADA classification: TB-500 is prohibited at all times under WADA S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics) and S0 (Non-Approved Substances). It is a non-Specified Substance carrying a maximum 4-year sanction. Competitive athletes face serious career consequences.

Is TB-500 Safe?

The honest research-based answer: animal studies report favorable tolerability; human safety data is limited to short-term Phase I trials of the full-length Tβ4 protein, which showed mostly mild, transient adverse events at doses up to 1260 mg IV in 40-person cohorts ^[9][10]. TB-500 (the 7-residue fragment) has no published human safety trial.

What is not known: long-term effects, effects at doses outside the Phase I trial ranges, the specific safety profile of the synthetic fragment (vs. the full protein), and the safety of chronic administration in the diverse health contexts where the compound is used outside of research.

The data supports cautious characterization as 'apparently tolerated in controlled animal studies and in human Phase I trials of the full protein.' It does not support characterization as 'proven safe' in a clinical sense.

Is TB-500 FDA Approved?

TB-500 is not FDA-approved for any human indication. It is studied as a research compound only.

Full-length Thymosin Beta-4 (the parent protein) has been investigated in human clinical trials: Phase I safety studies in healthy volunteers ^[9][10] and a Phase 2 ophthalmic trial for severe dry eye disease (Sosne et al. 2015) ^[8]. As of 2025, no FDA-approved product containing TB-500 or Thymosin Beta-4 for systemic human use has been authorized. RGN-259 (Tβ4 ophthalmic) completed Phase 2 trials but has not received FDA approval for dry eye disease as of this writing.

TB-500 is not classified as a controlled substance. It occupies a research-chemical status — legally complex, not pharmacologically categorized under the Controlled Substances Act.

Research Context and Cautions

Clinical commentary has noted that individuals with active malignancy, autoimmune conditions, or during pregnancy represent populations warranting particular caution — since Tβ4's pro-angiogenic and cell-migration-promoting effects are theoretically relevant in contexts where angiogenesis and cell proliferation are already dysregulated. These are not formal contraindications established by clinical trial data; they are theoretical cautions derived from mechanistic extrapolation.

This reading room does not provide medical guidance. The above mechanistic observations are drawn from the peer-reviewed literature and are offered as context for understanding the research discussions — not as clinical advice.